Clopidogrel and PPI Interaction: Clinically Relevant or Not?

被引:13
|
作者
Harrison, Robert W. [1 ]
Mahaffey, Kenneth W. [1 ]
机构
[1] Duke Clin Res Inst, Durham, NC 27715 USA
关键词
Clopidogrel; Proton pump inhibitors; Clopidogrel-PPI interaction; Acute coronary syndromes; PROTON-PUMP INHIBITORS; PERCUTANEOUS CORONARY INTERVENTION; MYOCARDIAL-INFARCTION; ANTIPLATELET THERAPY; CARDIOVASCULAR EVENTS; PLATELET REACTIVITY; CONCOMITANT USE; ARTERY-DISEASE; ASPIRIN; OMEPRAZOLE;
D O I
10.1007/s11886-011-0233-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Proton pump inhibitors and clopidogrel are commonly prescribed medications, both alone and in combination. In January of 2009 the US Food and Drug Administration and the European Medicines Agency issued warnings with regard to the concomitant use of clopidogrel and proton pump inhibitors. Later that year, these warnings were limited to the proton pump inhibitor omeprazole. These warnings were largely based on in-vitro studies and observational analyses suggesting decreased efficacy of clopidogrel in the presence of proton pump inhibitors. Recent literature has suggested there may not be a clinically meaningful interaction.
引用
收藏
页码:49 / 58
页数:10
相关论文
共 50 条
  • [1] Clopidogrel and PPI Interaction: Clinically Relevant or Not?
    Robert W. Harrison
    Kenneth W. Mahaffey
    Current Cardiology Reports, 2012, 14 : 49 - 58
  • [3] Interaction between statins and clopidogrel: is there anything clinically relevant
    Bhindi, R.
    Ormerod, O.
    Newton, J.
    Banning, A. P.
    Testa, L.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2008, 101 (12) : 915 - 925
  • [4] Interaction Clopidogrel and PPI
    Anditsch, M.
    JOURNAL FUR KARDIOLOGIE, 2009, 16 (11-12): : 448 - 450
  • [6] Clopidogrel–PPI interaction, an ongoing controversy
    Paul A. Gurbel
    Udaya S. Tantry
    Nature Reviews Cardiology, 2011, 8 : 7 - 8
  • [8] Clopidogrel-PPI interaction, an ongoing controversy
    Gurbel, Paul A.
    Tantry, Udaya S.
    NATURE REVIEWS CARDIOLOGY, 2011, 8 (01) : 7 - 8
  • [9] Evaluation of a Clinically Relevant Drug-Drug Interaction Between Rosuvastatin and Clopidogrel and the Risk of Hepatotoxicity
    Ning, Chen
    Su, Shengdi
    Li, Jiaming
    Kong, Dexuan
    Cai, Hui
    Qin, Zhiying
    Xing, Han
    Chen, Xijing
    He, Jiake
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [10] Identifying Clinically Relevant Sources of Variability: The Clopidogrel Challenge
    Samant, S.
    Jiang, X. L.
    Peletier, L. A.
    Shuldiner, A. R.
    Horenstein, R. B.
    Lewis, J. P.
    Lesko, L. J.
    Schmidt, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (02) : 264 - 273